Regeneron Hit With Eye Medicine Patent Challenge In UK
A biosimilars specialist and its licensing partner have challenged the validity of Regeneron's U.K. eye medicine patents amid their plans to market an alternative version, telling a London court that the...To view the full article, register now.
Already a subscriber? Click here to view full article